These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Relative bioavailability comparison of different coenzyme Q10 formulations with a novel delivery system. Liu ZX; Artmann C Altern Ther Health Med; 2009; 15(2):42-6. PubMed ID: 19284181 [TBL] [Abstract][Full Text] [Related]
4. Relative bioavailability of two forms of a novel water-soluble coenzyme Q10. Zmitek J; Smidovnik A; Fir M; Prosek M; Zmitek K; Walczak J; Pravst I Ann Nutr Metab; 2008; 52(4):281-7. PubMed ID: 18645245 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the relative bioavailability of different coenzyme Q10 formulations with a novel solubilizate (Solu Q10). Schulz C; Obermüller-Jevic UC; Hasselwander O; Bernhardt J; Biesalski HK Int J Food Sci Nutr; 2006; 57(7-8):546-55. PubMed ID: 17162333 [TBL] [Abstract][Full Text] [Related]
6. [Effect of coenzyme Q10 in patients with kidney diseases]. Gazdíková K; Gvozdjáková A; Kucharská J; Spustová V; Braunová Z; Dzúrik R Cas Lek Cesk; 2001 May; 140(10):307-10. PubMed ID: 11411060 [TBL] [Abstract][Full Text] [Related]
7. The uptake and distribution of coenzyme Q10. Miles MV Mitochondrion; 2007 Jun; 7 Suppl():S72-7. PubMed ID: 17446143 [TBL] [Abstract][Full Text] [Related]
8. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Haas RH Mitochondrion; 2007 Jun; 7 Suppl():S136-45. PubMed ID: 17485245 [TBL] [Abstract][Full Text] [Related]
9. Development of potent oral nanoparticulate formulation of coenzyme Q10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy? Ankola DD; Viswanad B; Bhardwaj V; Ramarao P; Kumar MN Eur J Pharm Biopharm; 2007 Sep; 67(2):361-9. PubMed ID: 17452099 [TBL] [Abstract][Full Text] [Related]
10. Assessment of coenzyme Q10 absorption using an in vitro digestion-Caco-2 cell model. Bhagavan HN; Chopra RK; Craft NE; Chitchumroonchokchai C; Failla ML Int J Pharm; 2007 Mar; 333(1-2):112-7. PubMed ID: 17092667 [TBL] [Abstract][Full Text] [Related]
11. Antioxidants, supplements, and Parkinson's disease. Weber CA; Ernst ME Ann Pharmacother; 2006 May; 40(5):935-8. PubMed ID: 16622156 [TBL] [Abstract][Full Text] [Related]
12. [Coenzyme q10 in childhood: detection methods, reference values and disease-related changes in the coenzyme q10 status]. Menke T Georgian Med News; 2008 Mar; (156):24-32. PubMed ID: 18403806 [TBL] [Abstract][Full Text] [Related]
13. Coenzyme Q10; an adjunctive therapy for congestive heart failure? Molyneux SL; Florkowski CM; Richards AM; Lever M; Young JM; George PM N Z Med J; 2009 Oct; 122(1305):74-9. PubMed ID: 19966871 [TBL] [Abstract][Full Text] [Related]
17. Relative bioavailability of coenzyme Q10 formulation for paediatric individualized therapy. Martinefski M; Samassa P; Buontempo F; Höcht C; Lucangioli S; Tripodi V J Pharm Pharmacol; 2017 May; 69(5):567-573. PubMed ID: 27464712 [TBL] [Abstract][Full Text] [Related]
18. The role of coenzyme Q10 in heart failure. Weant KA; Smith KM Ann Pharmacother; 2005 Sep; 39(9):1522-6. PubMed ID: 16046484 [TBL] [Abstract][Full Text] [Related]
19. Coenzyme Q10 and statins: biochemical and clinical implications. Littarru GP; Langsjoen P Mitochondrion; 2007 Jun; 7 Suppl():S168-74. PubMed ID: 17482884 [TBL] [Abstract][Full Text] [Related]
20. Coenzyme Q10 in phenylketonuria and mevalonic aciduria. Hargreaves IP Mitochondrion; 2007 Jun; 7 Suppl():S175-80. PubMed ID: 17442628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]